Alcobra Pharmaceuticals
Treatment of Cognitive Disorders
Company Overview
Snapshot
Founded in February 2008, Alcobra Pharmaceuticals operated with 1–10 employees. The company raised $25 million across one funding round and was acquired by Arcturus Therapeutics Inc. in November 2017.
Business overview
Alcobra Pharmaceuticals was an emerging pharmaceutical company focused on developing and commercializing Metadoxine Extended Release (MDX), a proprietary drug for cognitive disorders such as attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome. MDX, a non-stimulant, utilized a distinct mechanism of action compared to other ADHD treatments. The company conducted multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD, alongside separate phase 2b trials for pediatric ADHD and Fragile X syndrome. Alcobra Pharmaceuticals operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting patients in the healthcare market.
Strategic signal
In November 2017, Arcturus Therapeutics Inc. announced the completion of its merger with Alcobra Ltd. and commenced trading on the Nasdaq Global Market. This event marked Alcobra Pharmaceuticals' exit from the market through acquisition, signaling a strategic consolidation within the biotechnology and pharmaceutical sectors.
Company Intelligence Q&A
- What was the primary focus of Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals primarily focused on the development and commercialization of Metadoxine Extended Release (MDX), a proprietary drug designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome.
- When was Alcobra Pharmaceuticals acquired?
- Alcobra Pharmaceuticals was acquired by Arcturus Therapeutics Inc. in November 2017.
- What was the total capital raised by Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals raised a total of $25 million across one funding round.
- Did Alcobra Pharmaceuticals receive any special designations for its drugs?
- In September 2015, Alcobra was awarded fast track designation for its Fragile X drug.
- What was the outcome of Alcobra's Phase III ADHD drug results?
- In October 2014, Alcobra's stock plunged following the results of its Phase III ADHD drug trial.